This content is machine translated Global Recommendation, Swissmedic Approval, and SL Limitation WHO Guidelines on GLP-1 for Obesity With the guideline published on December 1, 2025, the World Health Organization has, for the first time, issued a globally applicable recommendation on the pharmacological management of obesity in adults....…
View Post 7 min This content is machine translated Obesity in Children and Adolescents Gene-Environment Interactions: Polygenic or Monogenic Determinants? In the context of precision medicine, a differentiated approach to the diagnosis of obesity provides an essential foundation for implementing improved strategies for prevention, treatment, and prognosis. Obesity is often...…
View Post 11 min This content is machine translated Cardiometabolism Retatrutid and the TRIUMPH Program: The Triple Agonist on the Horizon Incretin-based obesity therapy has advanced rapidly in just a few years: from GLP-1 receptor agonists (semaglutide) to the dual GIP/GLP-1 agonist tirzepatide and on to a triple agonist. Retatrutide (LY3437943)...…
View Post 12 min This content is machine translated Hepatology and Metabolism The Mediterranean Diet for MASLD/MASH—What the EASL-EASD-EASO Guidelines Specifically Recommend Since an international Delphi consensus in 2023, the condition formerly known as nonalcoholic fatty liver disease (NAFLD) has been called MASLD— “metabolic dysfunction-associated steatotic liver disease.” It is defined as...…
View Post 15 min This content is machine translated Obesity, Nutrition, and Mental Health Depression, Binge Eating, Internalized Stigma Cardiometabolic outcomes rightly dominate obesity care. However, the psychological dimension is by no means a footnote: depression, disordered eating, and an often-overlooked internalized weight stigma influence the burden of disease,...…
View Post 4 min This content is machine translated MASH Pharmacotherapies as “Game Changers”—What Are the Upcoming Challenges? Two drug therapy options—semaglutide (s.c.) and resmetirom (oral)—are now approved in the EU and the U.S. for the treatment of MASH. This is a major breakthrough, especially since, for a...…
View Post 6 min This content is machine translated MASLD/MASH: lifestyle, pharmacotherapy, bariatric procedures Addressing metabolic drivers and counteracting fibrosis Steatotic liver diseases that are not associated with alcohol consumption are now referred to as metabolic steatotic liver disease (MASLD) or metabolic dysfunction-associated steatohepatitis (MASH). There is now no need...…
View Post 8 min This content is machine translated Obesity treatment: new study data Incretin mimetics for comorbidities such as type 2 diabetes, ASCVD, HF, OSAS Lifestyle-related measures are the basic framework in the treatment of overweight and obesity. However, in order to achieve and maintain the target weight, accompanying pharmacological or surgical measures are usually...…
View Post 5 min This content is machine translated Heterogeneous safety profiles for dermatological and endocrine AEs Not all GLP1-RA are the same GLP1-RA effectively improve blood glucose, weight and cardiovascular parameters, but are increasingly in focus due to possible additional side effects such as alopecia and neuropsychiatric effects. A large real-world analysis...…
View Post 14 min This content is machine translated Heart failure and type 2 diabetes Oral semaglutide and cardiac decompensation in type 2 diabetes The secondary analysis of the SOUL trial from JAMA Internal Medicine 2026 proves for the first time: Oral semaglutide significantly reduces heart failure events in patients with pre-existing HFpEF –...…
View Post 6 min This content is machine translated Incretin mimetics for obesity and prediabetes Liraglutide, semaglutide and tirzepatide: considerable evidence base Weight reduction is an important therapeutic measure in diabetes prevention. Prediabetes is characterized by elevated fasting blood sugar and/or impaired glucose tolerance, but not yet manifest diabetes. In obese people,...…
